Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised double blind controlled phase III study to compare the efficacy and safety of intravenous iron carboxymaltose (ferinject) with placebo in patients with chronic heart failure and iron deficiency

Next Previous
Trial Profile

A randomised double blind controlled phase III study to compare the efficacy and safety of intravenous iron carboxymaltose (ferinject) with placebo in patients with chronic heart failure and iron deficiency

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms FAIR-HF
  • Sponsors Vifor

    • Most Recent Events

    • 13 Mar 2022 Results of pooled analysis from FAIR-HF and CONFIRM-HF assessing whether Treatment of iron-deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual-patient level, published in the European Journal of Heart Failure
    • 23 May 2016 Results published in Vifor Pharma media release.
    • 23 May 2016 According to Vifor Pharma media release, based upon the findings of this and other study (CONFIRM-HF), the 2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure (the ESC Guidelines HF 2016) recommended Ferinject for the treatment of iron deficiency in patients with systolic heart failure.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top